Engineered Dendritic Cells and Uses for the Treatment of Cancer

This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL- 12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

Patents:
WO 2,009,048,560

Inventor(s): BRAUGHLER J MARK [GB]; KUMAR PRASANNA [US]; STORKUS WALTER J [US]; OKADA HIDEHO [US]

Type of Offer: Licensing



« More Medical Patents

---